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Abstract
Objective: To compare the clinical outcomes after extraplaque (EP) versus
intraplaque (IP) tracking in chronic total occlusion (CTO) percutaneous coronary
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intervention (PCI).
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Background: The impact of modern dissection and reentry (DR) techniques on the
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long‐term outcomes of CTO PCI remains controversial.
Methods: We performed a systematic review and meta‐analysis of studies that
compared EP versus IP tracking in CTO PCI. Odds ratios (ORs) with 95% confidence
intervals (CIs) are calculated using the Der‐Simonian and Laird random‐effects
method.
Results: Our meta‐analysis included seven observational studies with 2982 patients.
Patients who underwent EP tracking had significantly more complex CTOs with
higher J‐CTO score, longer lesion length, and more severe calcification and had
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significantly longer stented segments. During a median follow‐up of 12 months
(range 9–12 months), EP tracking was associated with a higher risk of major adverse
cardiovascular events (MACE) (OR 1.50, 95% CI (1.10–2.06), p = 0.01) and target
vessel revascularization (TVR) (OR 1.69, 95% CI (1.15–2.48), p = 0.01) compared
with IP tracking. There was no difference in the incidence of all‐cause death (OR
1.37, 95% CI (0.67–2.78), p = 0.39), myocardial infarction (MI) (OR 1.48, 95% CI
(0.82–2.69), p = 0.20), stent thrombosis (OR 2.09, 95% CI (0.69–6.33), p = 0.19), or
cardiac death (OR 1.10, 95% CI (0.39–3.15), p = 0.85) between IP and EP tracking.
Conclusion: EP tracking is utilized in more complex CTOs and requires more stents.
EP tracking is associated with a higher risk of MACE, driven by a higher risk of TVR
at 1 year, but without an increased risk of death or MI compared with IP tracking. EP
tracking is critically important for contemporary CTO PCI.

Abbreviations: CTO, chronic total occlusion; DR, dissection and reentry; EP, extraplaque; IP, intraplaque; PCI, percutaneous coronary intervention.
Michael Megaly and Kevin Buda contributed equally.
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| INTRODUCTION

Chronic total occlusion (CTO) percutaneous coronary intervention (PCI)

2 |

METHODS

2.1 |

Search strategy

can be challenging, requiring various crossing strategies. The development
of extraplaque tracking (EP, also often called dissection and reentry [DR])

We conducted a systematic review of CTO PCI studies that

enabled the successful crossing of complex CTOs (e.g., tortuous, calcified,

compared EP versus IP. We performed a computerized search

and long CTOs, or CTOs with ambiguous proximal caps). EP tracking can

according to the proposal for conducting and reporting meta‐

be utilized in both the retrograde [retrograde dissection and reentry (RDR)

analyses of observational studies (MOOSE). We performed a

with controlled antegrade and retrograde subintimal tracking (CART) and

systematic search limited to the English language through

reverse CART)] and the antegrade [antegrade dissection and reentry

Medline, Embase, and Cochrane databases from January 2012

(ADR) with wire‐based or device‐based reentry] approach.

to January 2022 using the following search terms separately and

Some CTO crossing algorithms (e.g., the hybrid and APCTO

in combination; “chronic total occlusion,” “intraplaque,” “extra-

algorithms) 1,2 favor early adoption of EP tracking to achieve quicker

plaque,” “antegrade dissection and reentry,” “retrograde dissec-

success in complex CTOs, while others (e.g., the Euro CTO and

tion and reentry,” “ADR,” “RDR,” “CTO,” and “PCI.” We screened

3,4

limit the use of EP crossing (especially ADR)

the retrieved studies’ bibliographies for relevant studies not

to bail out after exhausting other options, due to concerns about the

found through the initial search. Two independent investigators

negative impact of EP tracking on CTO PCI outcomes. We performed

(KB and MM) performed the search, both physicians. The

a meta‐analysis to compare the follow‐up outcomes of EP versus IP

study's detailed search strategy and flowchart are shown in

tracking in CTO PCI.

Figure 1.

Japanese algorithms)

FIGURE 1
studies.

Flowchart of the included
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| Outcomes and definitions

3

ventricular ejection fraction, or comorbidities between both groups.
However, patients who underwent EP tracking were more likely to

The outcomes of our study were clinical adverse events at follow‐up: all‐

have had prior CABG (33% vs. 19.4%, p < 0.001).

cause death, cardiac death, myocardial infarction (MI), stent thrombosis,

Patients who underwent EP tracking had significantly more

ischemia‐driven target vessel revascularization (TVR), and major adverse

complex lesions including higher J‐CTO score (2.9 ± 1.2 vs. 1.6 ± 1.1,

cardiovascular events, defined as the composite of all‐cause death, MI, or

p < 0.001), longer CTOs (38.3 ± 23.4 vs. 24.7 ± 15.8 mm, p < 0.001),

TVR. Definitions of the study outcomes are shown in Table S1.

higher prevalence of moderate to severe calcification (55.7% vs.
42.3%, p < 0.001), more blunt stumps at the proximal cap (54.9% vs.
32.7%, p < 0.001), more bifurcations (38.9% vs. 29.1%, p < 0.001), and

2.3

| Statistical analysis

less in‐stent CTOs (7% vs. 10.7%, p = 0.009). They also received more
stents (2.2 ± 1.0 vs. 1.9 ± 0.9, p = 0.007) and had longer stent length

Categorical variables were reported as frequencies while continuous

(85.3 ± 38.1 vs. 53.5 ± 28.4 mm, p < 0.001).

variables as means with standard deviations (SD). Categorical
variables were compared using the Fisher's exact or Chi‐square
tests, while continuous variables were analyzed using the two‐sample

3.2 |

Wire position with imaging adjudication

t‐test. Tests were two‐tailed, and a p‐value of ≤ 0.05 was considered
statistically significant. All reported baseline characteristics and

Intravascular imaging was utilized to evaluate wire position after

outcomes were weighted, with the sample size being the weight.

crossing with true‐to‐true wiring techniques. Wire position was

Odds ratios (ORs) with 95% confidence intervals (CIs) are presented

extraplaque

as summary statistics. Statistical heterogeneity was assessed using

(24.2%–30.9%). When intentional EP tracking was utilized, the wire

the I2 statistic: I2 > 50% was considered substantial, and I2 > 75% was

position was IP in 11.8% of ADR and 16.7% of RDR cases in the

considered considerable. We used the Der‐Simonian and Laird

Consistent CTO study.12

with

AW

(11.6%–12.3%)

less

often

than

RW

random‐effects method to calculate OR, as we anticipated clinical
and methodological heterogeneity. Potential publication bias was
assessed using Egger's test by visually examining the funnel plots

3.3 |

Outcomes

(Figures S1 and S2). Bias assessment was calculated according to the
Newcastle‐Ottawa scale for observational studies (Table S2). We

During a median follow up of 12 months (range 9–12 months), EP

performed a sensitivity analysis, including studies that directly

tracking was associated with a higher risk of MACE (13.3% vs. 9.8%,

compared intentional EP versus IP tracking regardless of actual wire

OR 1.50, 95% CI [1.10–2.06], p = 0.01, I2 = 23.0%) and TVR (7.5% vs.

position as assessed by intravascular imaging. Statistical analyses

4.9%, OR 1.69, 95% CI [1.15–2.48], p = 0.01, I2 = 4.8%) compared

were performed using STATA software for Windows (version 17.0:

with IP tracking (Figure 1). There was no statistically significant

StataCorp LLC). Data are available on request. The study is a meta‐

difference in the incidence of all cause death (OR 1.37, 95% CI

analysis and, therefore, institutional board review (IRB) approval was

[0.67–2.78], p = 0.39, I2 = 0.0%), MI (OR 1.48, 95% CI [0.82–2.69],

not required.

p = 0.20, I2 = 0.0%), stent thrombosis (OR 2.09, 95% CI [0.69–6.33],
p = 0.19, I2 = 0.0%), or cardiac death (OR 1.10, 95% CI [0.39–3.15],
p = 0.85, I2 = 19.5%) between the study groups (Figures 2 and S3).

3

| RESULTS

When comparing intentional EP tracking with antegrade and
retrograde IP tracking regardless of imaging adjudication, EP tracking

Our meta‐analysis included seven observational studies with 2982
5–11

remained associated with higher risk of MACE (OR 1.42, 95% CI

(IP n = 1977, EP n = 1005). Three studies, including 689

[1.03–1.96], p = 0.03, I2 = 26.2%) and TVR (OR 1.76, 95% CI

patients, used intravascular imaging to adjudicate IP versus EP

[1.02–2.73], p = 0.04, I2 = 22.9%) (Figure 3). There was no statistical

tracking.6,8,9 In the Muramatsu et al. and Hasegawa et el. studies,

difference in the incidence of all cause death (OR 1.18, 95% CI

patients

The CONSISTENT CTO

[0.55–2.54], p = 0.68, I2 = 0.0%), MI (OR 1.44, 95% CI [0.78–2.66],

study compared outcomes between Intentional EP tracking versus

p = 0.24, I2 = 0.0%), or cardiac death (OR 0.72, 95% CI [0.29–1.77],

intentional EP tracking was not utilized.

6,8

9

true‐to‐true wiring. The remaining four studies compared EP versus
IP tracking outcomes without imaging adjudication. The character-

p = 0.47, I2 = 0.0%) between both groups (Figures 2 and S4).
A summary of the study results is shown in Figure 4.

istics of the included studies are shown in Table 1.

4 |
3.1

D IS CU SS IO N

| Characteristics of patients and lesions
Our study is the first meta‐analysis to evaluate the outcomes of EP

The characteristics of the included patients and lesions are shown in

versus IP tracking in modern CTO PCI. The main findings of our study

Table 2. Overall there was no difference in age, gender, left

can be summarized as follows: (1) The operator intended crossing
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J‐PROCTOR Registry

PROGRESS CTO
Registry

N/A

J‐PROCTOR 2

N/A

CONSISTENT CTO

ISAR‐CTO

Muramatsu
et al.8

Amsavelu et al.5

Azzalini et al.7

Hasegawa et al.6

Wilson et al.10

Walsh et al.9

Xhepa et al.11
N/A

IVUS
(AW:11.8% subintimal
RW: 26.5% subintimal
ADR: 11.8% intimal
RDR: 16.7% intimal)
OCT at follow‐up

N/A
(IVUS use only 15% and
not mandated)

IVUS
(AW: 11.6% subintimal
RW: 30.9% subintimal)

N/A

N/A

IVUS
(AW: 12.3% subintimal,
RW: 24.2%
subintimal)

Imaging adjudication

403/70

109/191

430/375

270/53

571/258

RCA: 47
LAD: 28
LCx: 28
LM: 0.4

N/A

N/A

N/A

RCA: 53
LAD: 29
LCx:19

N/A

RCA: 59
LAD: 29
LCx: 12
LM: 1

125/31

90/83

CTO‐related
artery (%)

N intimal/
subintimal

Germany (1)

UK (6)

UK (7)

Japan (30)

Italy, Canada, US,
Spain (4)

12

24

12

12

12

12

12

Japan (27)

US (1)

Follow‐up time
(months)

Country (number
of centers)

Antegrade wiring and
retrograde approach but
Intentional ADR not included

Techniques utilized

Antegrade wiring and
retrograde approach
Intentional ADR not
performed

Modern ADR techniques

2015–2018

December
2014–December 2016

AW, RW, and dissection
reentry technique utilized

January 2012–March 2014 Intentional ADR and RDR
techniques compared with
AW and RW

January
2012–December 2012

January 2010–May 2016

January 2012–March 2015 ADR and RDR

October
2010–October 2011

Enrollment time

|
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Abbreviations: CONSISTENT‐CTO, Conventional Antegrade Versus Sub‐Intimal Synergy Stenting in Chronic Total Occlusions; CTO PCI, chronic total occlusion percutaneous coronary intervention; IH, in‐
hospital; ISAR: Intracoronary Stenting and Angiographic Results – Chronic Total Occlusion; IVUS, intravascular ultrasound; J‐PROCTOR, (PROmus stent treatment of Chronic Total Occlusions using two
different Recanalization techniques in Japan); LAD, left anterior descending artery; LCx, left circumflex artery; LM, left mainstem artery; MACE, major adverse cardiovascular events; MI, myocardial infarction;
PMI, periprocedural MI; PROGRESS‐CTO, PROspective Global Registry for the Study of Chronic Total Occlusion Intervention; RCA, right coronary artery; TLR, target lesion revascularization; TVR, target vessel
revascularization; UK, United Kingdom; US, United States.

Trial/registry name

Characteristics of the included studies

Study

TABLE 1

4
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TABLE 2

5

Comparison of intraplaque versus extraplaque tracking during chronic total occlusion percutaneous coronary intervention
IntraplaqueN = 7 studies (1977
patients)

ExtraplaqueN = 7 studies (1005
patients)

Age mean ± SD

65.9 ± 8.5 [1172]

65.2 ± 8.7 [473]

0.133

Male %

89.4 [1172]

89.8 [473]

0.880

Diabetes %

41.2 [1172]

43.6 [473]

0.402

Hypertension %

80.3 [1172]

82.7 [473]

0.292

Dyslipidemia %

72.7 [1172]

83.9 [473]

<0.001

Active smoking %

22.3 [1172]

26.4 [473]

0.087

Previous MI %

40.6 [1172]

50.8 [473]

<0.001

Previous PCI %

52.0 [661]

60.0 [405]

0.013

Previous CABG %

19.4 [1172]

33.0 [473]

<0.001

2

p‐value

Baseline characteristics and hemodynamic parameters

Multivessel disease %

84.5 [511]

78.8 [99]

0.210

LVEF mean ± SD

50.1 ± 10.3 [1047]

50.7 ± 11.6 [442]

0.323

J‐CTO Score mean ± SD

1.6 ± 1.1 [1582]

2.9 ± 1.2 [921]

<0.001

67.2 [957]2

78.8 [326]2

<0.001

Presentation
Stable angina

2

2

12.9 [957]

8.2 [326]

CTO length

24.7 ± 15.8 [1136]

38.3 ± 23.4 [694]

<0.001

Moderate‐severe calcification

43.7 [1598]

55.7 [851]

<0.001

Proximal tortuosity

42.3 [215]

50.5 [147]

0.152

Blunt stump

32.7 [661]

54.9 [374]

<0.001

Bifurcation

29.1 [1212]

38.9 [783]

<0.001

In‐stent CTO

10.7 [1087]

7.0 [752]

0.009

2.8 ± 0.6 [234]2

3.0 ± 0.6 [132]2

Unstable angina/ACS

0.029

CTO related artery

Procedural characteristics
MLD, mean ± SD

2

2

0.002

Number of stents, mean ± SD

1.9 ± 0.9 [395]

2.2 ± 1.0 [84]

Stent length mean ± SD

53.5 ± 28.4 [1568]

85.3 ± 38.1 [596]

Maximum stent diameter, mean ± SD

3.1 ± 0.4 [798]

3.2 ± 0.5 [154]

0.007

Maximum expansion pressure (atm), mean ± SD

16.0 ± 3.1 [798]

15.6 ± 3.2 [154]

0.145

Contrast volume (ml), mean ± SD

274.0 ± 105.4 [1244]

Fluoroscopy time (min)
Procedure time (min)

2

43.7 ± 30.1 [841]

2

111.5 ± 65.5 [841]

0.007
<0.001

358.8 ± 122.7 [381]

<0.001

72.2 ± 38.1 [311]

<0.001

185.2 ± 80.7 [53]

<0.001

Abbreviations: BMI, body mass index; CABG, coronary artery bypass graft; CTO, chronic total occlusion; J‐CTO, Japan‐Chronic Total Occlusion Score;
LAD, left anterior descending; LCx, left circumflex; LM, left mainstem; LVEF, left ventricular ejection fraction; MACE, major adverse cardiovascular events;
MI, myocardial infarction; MLD, minimal luminal diameter; PCI, percutaneous coronary intervention; RCA, right coronary artery; RVD, reference vessel
diameter; TLR, target lesion revascularization; TVR, target vessel revascularization
*Numbers between square brackets represent the number of subjects with a reported variable when different from the baseline.
2

Only two studies reported data.

technique (IP or EP) does not correspond with the actual crossing type

calcification, required more stents wand had significantly longer

in approximately 10% of antegrade cases and 15%–30% of retrograde

stented segments, and (3) EP tracking was associated with a higher

cases, (2) Patients who underwent EP tracking had significantly more

risk of MACE driven by a higher risk of TVR at 1 year compared with IP

complex CTOs with higher J‐CTO score, longer lesions, and severe

tracking but without impact on death or MI.

1522726x, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/ccd.30403 by Henry Ford Health System, Wiley Online Library on [11/10/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

MEGALY

|

MEGALY

ET AL.

F I G U R E 2 Forrest plots of major adverse cardiovascular events, all‐cause death, myocardial infarction, and target vessel revascularization in patients
undergoing chronic total occlusion percutaneous coronary intervention with extraplaque versus intraplaque crossing. MACE, major adverse
cardiovascular events; MI, myocardial infarction; TVR, target vessel revascularization. [Color figure can be viewed at wileyonlinelibrary.com]

F I G U R E 3 Forrest plots of major adverse cardiovascular events, all‐cause death, myocardial infarction, and target vessel revascularization in patients
undergoing chronic total occlusion percutaneous coronary intervention with dissection reentry techniques versus not. MACE, major adverse
cardiovascular events; MI, myocardial infarction; TVR, target vessel revascularization. [Color figure can be viewed at wileyonlinelibrary.com]
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F I G U R E 4 Summary of the study results. ADR, antegrade dissection and reentry; AW, antegrade wiring; DR, dissection and reentry; MACE,
major adverse cardiovascular events; MI, myocardial infarction; RDR, retrograde dissection and reentry; RW, retrograde wiring; TVR, target
vessel revascularization. [Color figure can be viewed at wileyonlinelibrary.com]

In 2006, Surmely et al. described the use of the CART technique
13

loss with EP crossing,8 and Hasegawa et al. showed a higher risk of

The development of the Corsair

TVR with EP tracking.6 Our analysis increased the power of individual

microcatheter (ASAHI Intecc) led to the development of the reverse

studies and showed higher MACE driven by higher TVR with EP

CART technique, followed by wider adoption of the retrograde

compared with IP tracking. This effect persisted after the sensitivity

approach.14 Colombo et al. described the antegrade subintimal

analysis, including studies comparing intentional ADR versus true‐to‐

tracking and re‐entry (STAR) technique in 2005,15 using a polymer‐

true lumen crossing. Our findings correlate with the cumulative

jacketed knuckled wire that spontaneously reentered in the true

knowledge of the higher risk of side branch loss, periprocedural MI,

lumen, usually at a distal bifurcation. Although multiple iterations and

and longer stent length with EP tracking. Although the impact of

improvements of wire‐based ADR followed, including the mini‐STAR

periprocedural MI and side branch loss on long‐term outcomes

technique,16 it remained associated with high restenosis and

remains unclear, our analysis showed no difference in MI or death

reocclusion rates (44% and 25% for STAR and mini‐STAR at 2

between both groups at 1 year. Our findings, however, should be

years).17 The development of device‐based reentry (Stingray system,

interpreted with caution and within their limitations, given the

Boston Scientific) increased reentry's predictability and improved

observational nature of the included studies, which carries a

ADR techniques’ outcomes compared with the wire‐based reentry.18

significant risk of selection bias. Less complex CTOs tend to be

Multiple studies have shown that assessing guidewire courses

solved more with IP techniques. EP tracking is usually used in more

based on technique is not always accurate. In our study, wire position

complex CTOs and with the retrograde approach.5,6,8 EP tracking was

was different than expected in approximately 10% of antegrade

associated with significantly longer stented segments, which is

cases and 15%–30% of retrograde cases. This is consistent with other

associated with higher TVR.20,21

in 10 patients with 100% success.

studies: Song et al. showed that IP tracking occurred in only 77% of

The significant improvement in CTO PCI success over the last

AW and 44% of RW cases. Predicting the retrograde wire course is

two decades (from 77%22 to 85% to 90% in experienced centers23,24]

more difficult than the antegrade wire course. RDR is favored over

can be attributed to multiple factors but mainly due to the adoption

RW in many retrograde CTO PCIs.

of algorithmic approaches (such as the hybrid algorithm)1 and the

Individual studies have shown that EP tracking did not adversely
5

development of the retrograde and ADR approaches. Although our

affect clinical outcomes or healing by optical coherent tomography

study showed higher TVR with EP tracking, these techniques remain

at 12 months.9 However, other studies have shown an increased risk

an indispensable tool in CTO PCI. The recommendations for EP

of periprocedural MI with EP tracking, mainly due to loss of side

tracking (especially ADR) vary according to the algorithm used and

branches.19 Muramatsu et al. showed greater angiographic lumen

operator preference. However, all CTO operators should be familiar
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with these advanced techniques to achieve high success rates. When
using EP tracking, operators should strive to minimize the EP tracking
length. and preserve side branches at the proximal and distal cap.

RE F ER EN CES
1.

18,25

2.

4.1

| Limitations
3.

Our study has several limitations. First, we only included observa-

4.

tional studies as no randomized controlled trials have been
performed. Second, the use of EP tracking was at the operators’
discretion. Third, CTOs treated with EP tracking were much more

5.

complex than CTOs treated with IP tracking, and the outcomes
described should be interpreted within these limitations. Finally, the
duration of follow‐up was limited to 1 year.

4.2

6.

| Conclusion
7.

EP tracking is utilized in more complex CTOs and requires more
stents. EP tracking is associated with a higher risk of MACE, driven by
a higher risk of TVR at one year, but without an increased risk of

8.

death or MI compared with IP tracking. EP tracking is critically
important for contemporary CTO PCI.
9.
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